Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Everist Genomics Announces New Data on OncoDefenderâ„¢- CRC Test for Predicting Recurrence Risk for Stage I and II Colorectal Cancer Patients

June 3, 2011 By Bio-Medicine.Org

CHICAGO, and ANN ARBOR, Mich., June 3, 2011 /PRNewswire/ —
Everist Genomics today announced updated results from a study of
its OncoDefender-CRC assay, a molecular prognostic test for
early-stage colorectal cancer patients, will be presented at the
2011 American Society of Clinical Oncology (ASCO) Annual Meeting,
which will be held June 3-7, 2011, in Chicago.

(Logo: http://photos.prnewswire.com/prnh/20110110/NY26865LOGO)

OncoDefender-CRC examines expression levels of a panel of genes
extracted from formalin-fixed paraffin-embedded cancer tissue taken
at the time of surgery, and uses a proprietary computer-generated
decision rule to stratify patients into ‘high-risk’ and ‘low-risk’
categories for assessing likelihood of recurrence.  

Accurately identifying Stage I/II colorectal cancer patients who
are at risk of recurrence represents a significant unmet medical
need as mortality rates for early stage disease are higher than
generally realized. “About one in seven patients with Stage I and
one in three patients with Stage II colorectal cancer will
ultimately experience a recurrence,” said Peter F. Lenehan, M.D.,
Ph.D. Chief Medical Officer of Everist Genomics. “In this
sub-population of patients who recur, the associated mortality
rates are 50 percent and 80 percent, respectively.”

The study confirmed that OncoDefender-CRC was able to
differentiate those patients at high risk from those at low risk
for cancer recurrence within 3 years after potentially curative
surgery more accurately than assessments based on National
Comprehensive Cancer Network (NCCN) Guidelines, widely accepted as
providing “best practices” in oncology.  The study included
patient samples from four international sites.

For stages I/II colorectal cancer (n=115), OncoDefender-CRC
correctly classified 32/46 cases of recurrence and 38/69 cases of
non-recurrence (sensitivity 70%, specif

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech